The global antihistamine product market was valued at US$ 263.9 billion in 2022. The market is expected to expand at a CAGR of 8.6% and reach a valuation of ~US$ 647.7 billion by 2033.
| Data Points | Market Insights |
|---|---|
| Antihistamine Market Value, 2022 | US$ 263.9 billion |
| Antihistamine Market Value, 2023 | US$ 284.2 billion |
| Antihistamine Market Value, 2033 | US$ 647.7 billion |
| CAGR (2023 to 2033) | 8.6% |
| Market Share of Top 5 Countries | 50.5% |
| Key Market Players | GlaxoSmithKline PLC., Sanofi Consumer Healthcare, Himalaya Wellness Company, Sun Pharmaceutical Industries, Inc., Bayer AG, Novartis AG, Cadila Pharmaceuticals, Bausch Health Companies Inc., Alcon Vision LLC., Merck & Co., Dr. Reddy’s Laboratories, Ltd., Viatris Inc., Somerset Pharma, LLC, F. Hoffmann- La Roche Ltd., Akorn Operating Company LLC, Teva Pharmaceutical Industries Ltd., Speer laboratories, Glenmark Pharmaceuticals Limited, TerSera Therapeutics LLC, Pfizer Inc., Morepen Laboratories Limited, Johnson & Johnson Sevices Inc., Pharmaceutical Specialties Inc., Proctor & Gamble |
The antihistamine market has observed significant growth over the last decade. The increasing prevalence of allergies and allergic reactions across the globe has expanded the growth of the antihistamine market. Antihistamine drugs are used to treat a variety of allergies and allergic reactions, as it is an anti-allergic medication. The body acts on certain histamine receptors and releases histamine throughout an allergic reaction. Antihistamine can also treat pruritus-related conditions such as atopic dermatitis, insect bites, and other conditions. Moreover, H-1 and H-2 types of antihistamine are used to treat other conditions such as insomnia, motion sickness, anxiety and heartburn, gastric ulcers, and others, respectively.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for antihistamines was approximately 1.3% of the overall global allergy treatment market worth ~US$ 19,070.0 billion in 2022.
| Historical Antihistamine Market Value (2022) | US$ 263.9 billion |
|---|---|
| Historical CAGR (2017 to 2022) | 5.9% |
The sale of antihistamines expanded at a CAGR of 5.9% from 2017 to 2022. The demand for antihistamine products will keep up strong in the years ahead. The preference for antihistamine drugs for treatment procedures is growing as the accessibility of these drugs is highly convenient through retail pharmacies, hospital pharmacies, and online pharmacies. This is one of the factors influencing the production growth of antihistamines. Numerous manufacturers are utilizing different antihistamine dosage forms to enhance their market share.
Allergic reactions caused on the skin are distinguished by red, peeling, dry, swollen surface, itch, and rash. The most common triggering factor for allergies is the overreaction of histamine in the body; this is when antihistamines come into action. Antihistamines assist in reducing inflammation, which usually alleviates the pain. Apart from that, skin conditions such as allergic rhinitis can occur due to prolonged and repeated exposure to dust mites, molds, or pet dander. It can further lead to symptoms such as nasal congestion and irritation in the nose, throat, and eyes, increasing the growth of the antihistamine market.
Medical professionals prescribe antihistamines to relieve symptoms of insomnia as well. Due to the current environment and lifestyle, such as unstable working shifts, smoking, varied sleeping patterns and others, the antihistamine market has witnessed growth in conditions such as insomnia, which is the most common issue among the general population today. According to an article published by the American Journal of Managed Care in 2020, around 30% to 40% of the U.S adult population develop symptoms of insomnia per year. The inability to fall asleep or stay asleep can have a major influence on productivity and mood. It can be a symptom or a cause of other underlying medical disorders. Easily available over-the-counter drugs such as diphenhydramine can assist in sleeping aids. An antihistamine is not a first-line treatment for insomnia but first-generation antihistamine blocks H-1 histamine receptors, which can cause sedation and make the patients drowsy. These factors can be favorable for the antihistamine market.
Thus, owing to the aforementioned factors, the global market is expected to grow at a CAGR of 8.6% during the forecast period from 2023 to 2033.
The growth will be driven by the increasing concerns regarding the prevalence of allergic reactions and other conditions such as urticaria and anxiety across the globe. Further, the market opportunistic outlook is owing to the increasing investments in research and development, due to which drug approvals are rising and new products concerning antihistamine drugs are being launched, which is expanding the market.
For instance, in May 2022, Glenmark Pharmaceuticals launched a nasal spray in India named Ryaltris-AZ. Ryaltris-AZ was introduced as the first-line treatment for allergic rhinitis with a mixture of intranasal antihistamines and corticosteroids.
Moreover, a number of manufacturers are expanding their line of medications by providing antihistamine drugs in multiple routes of administration, increasing the range of antihistamine-related products in the market. Hence, in the forthcoming years, the antihistamine market is expected to dispense lucrative growth opportunities.
Principal Consultant
Sometimes, due to a lack of awareness among the rural population in some developing countries, it becomes difficult to cope with allergies and other conditions. It is because of negligence and inability to seek medical help. This is a crucial factor hampering the growth of the market.
Antihistamine blocks the process of histamine, but at times, there are a few side effects that can be caused due to antihistamines. These side effects include drowsiness, dry mouth, dry eyes, sore throat, and others. This factor acts as a barrier and affects the growth of the market in a negative manner.
| Countries | CAGR (2023 to 2033) |
|---|---|
| United States | 8.9% |
| China | 8.6% |
| United Kingdom | 8.0% |
| Germany | 8.2% |
| India | 7.8% |
The United States dominates the North American region, with a total market share of about 85.4% in 2022. The market is expected to grow at a CAGR of 8.9% through 2033.
According to the Centers for Disease Control and Prevention, more than 60 million people per year in the United States suffer from hay fever. It was also reported that seven out of ten patients in 2020 were suffering from hay fever along with allergic conjunctivitis that causes red, watery, and itchy eyes. The prevalence of allergies in the U.S. is driving the market. There are numerous antihistamine medications that provide relief from such inflammation symptoms. These are the prime drivers for the market within the country.
China dominates the East Asian region with a total market share of about 51.2%. It is estimated to grow at a CAGR of 8.6% throughout the forecast period.
Allergic rhinitis is becoming a major concern in terms of health and economy in China. Children in China are more prone to such disorders due to allergens like house dust mites. As the prevalence of allergies and allergic reactions is rising, the demand for antihistamines is increasing, boosting market growth.
India is set to exhibit a CAGR growth rate of nearly 7.8% during the forecast period. Due to the increasing prevalence of allergic conjunctivitis in the general population of India, the consumption of the antihistamines for the treatment is increasing, contributing to the growth of the Indian market.
Allergy-based disorders in India are becoming a matter of concern due to factors like the illiteracy among the rural population and paucity of allergy specialists.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Top Product | H-1 blockers |
|---|---|
| CAGR (2023 to 2033) | 8.9% |
H-1 blockers are expected to present high growth at a CAGR of 8.9% over the forecast period, with a market share of about 55.9%. H-1 antihistamines can alleviate the pain caused by allergic conjunctivitis, skin rashes and hypersensitivity toward certain drugs.
| Top Type | Over-the-counter |
|---|---|
| CAGR (2023 to 2033) | 9.0% |
Over-the-counter antihistamines are dominating the market with a share of 51.3% in 2022. This segment is expected to present high growth at a CAGR of 9.0% by the end of the forecast period. Antihistamine drugs are easily available through over-the-counter means. Therefore, this segment is considered to be dominant in the type category.
| Top Dosage | Tablets |
|---|---|
| CAGR (2023 to 2033) | 9.7% |
Tablets hold a market share of 35.0% in 2022 and are expected to display gradual growth over the forecast period, with a CAGR of 9.7%. Tablets are one the most convenient and economical dosage forms of antihistamines.
| Top Route of Administration | Oral |
|---|---|
| CAGR (2023 to 2033) | 8.0% |
The oral route of administration is dominating the market and is expected to grow at a CAGR of 8.0% over the forecast period, with a market share of about 48.7% in the global market in 2031. Oral medications are quite advantageous as compared to parental and topical medications. These advantages include patient preference, the convenience of drug administration, and cost-effectiveness.
| Top Distribution Channel | Hospital pharmacies |
|---|---|
| CAGR (2023 to 2033) | 9.1% |
Hospital pharmacies hold a prominent market share value of 42.9% during the year 2022 with a CAGR of 9.1%. The increasing number of hospital pharmacies is a factor contributing to the prominent share of hospital pharmacies in the distribution channel category.
The market is a highly fragmented market with numerous key players. To meet consumer demands and strengthen their presence worldwide, these companies are executing a new range of products and regulatory approvals. Few of the key developmental strategies of market players are given below:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, France, Italy, UK, Spain, Russia BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa |
| Key Market Segments Covered | Product, Type, Dosage Forms, Route of Administration, Indication, Distribution Channel and Region |
| Key Companies Profiled | GlaxoSmithKline PLC.; Sanofi Consumer Healthcare; Himalaya Wellness Company; Sun Pharmaceutical Industries, Inc.; Bayer AG; Novartis AG; Cadila Pharmaceuticals; Bausch Health Companies Inc.; Alcon Vision LLC.; Merck & Co.; Dr. Reddy’s Laboratories, Ltd.; Viatris Inc.; Somerset Pharma, LLC; F. Hoffmann- La Roche Ltd.; Akorn Operating Company LLC; Teva Pharmaceutical Industries Ltd.; Speer laboratories; Glenmark Pharmaceuticals Limited; TerSera Therapeutics LLC; Pfizer Inc.; Morepen Laboratories Limited; Johnson & Johnson Services Inc.; Pharmaceutical Specialties Inc.; Proctor & Gamble |
| Pricing | Available upon Request |
The global antihistamine market is worth US$ 263.9 billion in 2022.
The antihistamine market is expected to reach US$ 647.7 billion by 2033, growing at a CAGR of 8.6% over the forecast period.
Increased efficacy of antihistamines with respect to relieving symptoms and allergic reactions across the globe.
North America dominated the global antihistamine market accounting for a prominent market share of 34.6%.
The market in India is likely to grow with a CAGR of 7.8% over the forecast period.
The United States, China, the United Kingdom, Germany, and India are the top five countries, which are expected to drive demand for antihistamines.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. PESTLE Analysis
4.4. Porter Analysis
4.5. Regulatory Scenario
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Allergy Treatment Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Historic Growth of the Top Companies
5.2.2. Rising Prevalence of Allergies and Allergic Reactions
5.2.3. Mergers and Acquisitions
5.2.4. Strategic Collaborations
5.2.5. Adoption Rate
5.2.6. Product and Stock Availability
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Billion) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Billion) Analysis, 2017 to 2022
6.2. Current and Future Market Value (US$ Billion) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Product
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Billion) Analysis By Product, 2017 to 2022
7.3. Current and Future Market Size (US$ Billion) and Analysis and Forecast By Product, 2023 to 2033
7.3.1. H-1 Blockers
7.3.2. H-2 Blockers
7.4. Market Attractiveness Analysis By Product
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Billion) Analysis By Type, 2017 to 2022
8.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Type, 2023 to 2033
8.3.1. Prescription-based
8.3.2. Over-the-counter
8.4. Market Attractiveness Analysis By Type
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Dosage Forms
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Billion) Analysis By Dosage Forms, 2017 to 2022
9.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Dosage Forms, 2023 to 2033
9.3.1. Tablets
9.3.2. Capsules
9.3.3. Liquids
9.3.4. Other
9.4. Market Attractiveness Analysis By Dosage Forms
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Billion) Analysis By Route of Administration, 2017 to 2022
10.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Route of Administration, 2023 to 2033
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Billion) Analysis By Indication, 2017 to 2022
11.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Indication, 2023 to 2033
11.3.1. Allergies
11.3.2. Urticaria
11.3.3. Dermatitis
11.3.4. Others
11.4. Market Attractiveness Analysis By Indication
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Billion) Analysis By Distribution Channel, 2017 to 2022
12.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Distribution Channel, 2023 to 2033
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Drug Stores
12.3.4. Online Pharmacies
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Billion) Analysis By Region, 2017 to 2022
13.3. Current Market Size (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
14.3. Market Size (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Type
14.3.4. By Dosage Forms
14.3.5. By Route of Administration
14.3.6. By Indication
14.3.7. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Type
14.4.4. By Dosage Forms
14.4.5. By Route of Administration
14.4.6. By Indication
14.4.7. By Distribution Channel
14.5. Country Level Analysis & Forecast
14.5.1. USA Market Analysis
14.5.1.1. Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Product
14.5.1.2.2. By Type
14.5.1.2.3. By Dosage Forms
14.5.1.2.4. By Route of Administration
14.5.1.2.5. By Indication
14.5.1.2.6. By Distribution Channel
14.5.2. Canada Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Product
14.5.2.2.2. By Type
14.5.2.2.3. By Dosage Forms
14.5.2.2.4. By Route of Administration
14.5.2.2.5. By Indication
14.5.2.2.6. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
15.3. Market Size (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Type
15.3.4. By Dosage Forms
15.3.5. By Route of Administration
15.3.6. By Indication
15.3.7. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Type
15.4.4. By Dosage Forms
15.4.5. By Route of Administration
15.4.6. By Indication
15.4.7. By Distribution Channel
15.5. Country Level Analysis & Forecast
15.5.1. Brazil Market Analysis
15.5.1.1. Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Product
15.5.1.2.2. By Type
15.5.1.2.3. By Dosage Forms
15.5.1.2.4. By Route of Administration
15.5.1.2.5. By Indication
15.5.1.2.6. By Distribution Channel
15.5.2. Mexico Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Product
15.5.2.2.2. By Type
15.5.2.2.3. By Dosage Forms
15.5.2.2.4. By Route of Administration
15.5.2.2.5. By Indication
15.5.2.2.6. By Distribution Channel
15.5.3. Argentina Market Analysis
15.5.3.1. Introduction
15.5.3.2. Market Analysis and Forecast by Market Taxonomy
15.5.3.2.1. By Product
15.5.3.2.2. By Type
15.5.3.2.3. By Dosage Forms
15.5.3.2.4. By Route of Administration
15.5.3.2.5. By Indication
15.5.3.2.6. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
16.3. Market Size (US$ Billion) Forecast, By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. France
16.3.1.3. Italy
16.3.1.4. UK
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. BENELUX
16.3.1.8. Nordic Countries
16.3.1.9. Rest of Europe
16.3.2. By Product
16.3.3. By Type
16.3.4. By Dosage Forms
16.3.5. By Route of Administration
16.3.6. By Indication
16.3.7. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Type
16.4.4. By Dosage Forms
16.4.5. By Route of Administration
16.4.6. By Indication
16.4.7. By Distribution Channel
16.5. Country Level Analysis & Forecast
16.5.1. Germany Market Analysis
16.5.1.1. Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Product
16.5.1.2.2. By Type
16.5.1.2.3. By Dosage Forms
16.5.1.2.4. By Route of Administration
16.5.1.2.5. By Indication
16.5.1.2.6. By Distribution Channel
16.5.2. France Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Product
16.5.2.2.2. By Type
16.5.2.2.3. By Dosage Forms
16.5.2.2.4. By Route of Administration
16.5.2.2.5. By Indication
16.5.2.2.6. By Distribution Channel
16.5.3. Italy Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Product
16.5.3.2.2. By Type
16.5.3.2.3. By Dosage Forms
16.5.3.2.4. By Route of Administration
16.5.3.2.5. By Indication
16.5.3.2.6. By Distribution Channel
16.5.4. UK Market Analysis
16.5.4.1. Introduction
16.5.4.2. Market Analysis and Forecast by Market Taxonomy
16.5.4.2.1. By Product
16.5.4.2.2. By Type
16.5.4.2.3. By Dosage Forms
16.5.4.2.4. By Route of Administration
16.5.4.2.5. By Indication
16.5.4.2.6. By Distribution Channel
16.5.5. Spain Market Analysis
16.5.5.1. Introduction
16.5.5.2. Market Analysis and Forecast by Market Taxonomy
16.5.5.2.1. By Product
16.5.5.2.2. By Type
16.5.5.2.3. By Dosage Forms
16.5.5.2.4. By Route of Administration
16.5.5.2.5. By Indication
16.5.5.2.6. By Distribution Channel
16.5.6. Russia Market Analysis
16.5.6.1. Introduction
16.5.6.2. Market Analysis and Forecast by Market Taxonomy
16.5.6.2.1. By Product
16.5.6.2.2. By Type
16.5.6.2.3. By Dosage Forms
16.5.6.2.4. By Route of Administration
16.5.6.2.5. By Indication
16.5.6.2.6. By Distribution Channel
16.5.7. Nordic Countries Market Analysis
16.5.7.1. Introduction
16.5.7.2. Market Analysis and Forecast by Market Taxonomy
16.5.7.2.1. By Product
16.5.7.2.2. By Type
16.5.7.2.3. By Dosage Forms
16.5.7.2.4. By Route of Administration
16.5.7.2.5. By Indication
16.5.7.2.6. By Distribution Channel
16.5.8. BENELUX Market Analysis
16.5.8.1. Introduction
16.5.8.2. Market Analysis and Forecast by Market Taxonomy
16.5.8.2.1. By Product
16.5.8.2.2. By Type
16.5.8.2.3. By Dosage Forms
16.5.8.2.4. By Route of Administration
16.5.8.2.5. By Indication
16.5.8.2.6. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
17.3. Market Size (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Thailand
17.3.1.3. Indonesia
17.3.1.4. Malaysia
17.3.1.5. Rest of South Asia
17.3.2. By Product
17.3.3. By Type
17.3.4. By Dosage Forms
17.3.5. By Route of Administration
17.3.6. By Indication
17.3.7. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Type
17.4.4. By Dosage Forms
17.4.5. By Route of Administration
17.4.6. By Indication
17.4.7. By Distribution Channel
17.5. Country Level Analysis & Forecast
17.5.1. India Market Analysis
17.5.1.1. Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Product
17.5.1.2.2. By Type
17.5.1.2.3. By Dosage Forms
17.5.1.2.4. By Route of Administration
17.5.1.2.5. By Indication
17.5.1.2.6. By Distribution Channel
17.5.2. Thailand Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Product
17.5.2.2.2. By Type
17.5.2.2.3. By Dosage Forms
17.5.2.2.4. By Route of Administration
17.5.2.2.5. By Indication
17.5.2.2.6. By Distribution Channel
17.5.3. Indonesia Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Product
17.5.3.2.2. By Type
17.5.3.2.3. By Dosage Forms
17.5.3.2.4. By Route of Administration
17.5.3.2.5. By Indication
17.5.3.2.6. By Distribution Channel
17.5.4. Malaysia Market Analysis
17.5.4.1. Introduction
17.5.4.2. Market Analysis and Forecast by Market Taxonomy
17.5.4.2.1. By Product
17.5.4.2.2. By Type
17.5.4.2.3. By Dosage Forms
17.5.4.2.4. By Route of Administration
17.5.4.2.5. By Indication
17.5.4.2.6. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
18.3. Market Size (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Type
18.3.4. By Dosage Forms
18.3.5. By Route of Administration
18.3.6. By Indication
18.3.7. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Type
18.4.4. By Dosage Forms
18.4.5. By Route of Administration
18.4.6. By Indication
18.4.7. By Distribution Channel
18.5. Country Level Analysis & Forecast
18.5.1. China Market Analysis
18.5.1.1. Introduction
18.5.1.2. Market Analysis and Forecast by Market Taxonomy
18.5.1.2.1. By Product
18.5.1.2.2. By Type
18.5.1.2.3. By Dosage Forms
18.5.1.2.4. By Route of Administration
18.5.1.2.5. By Indication
18.5.1.2.6. By Distribution Channel
18.5.2. Japan Market Analysis
18.5.2.1. Introduction
18.5.2.2. Market Analysis and Forecast by Market Taxonomy
18.5.2.2.1. By Product
18.5.2.2.2. By Type
18.5.2.2.3. By Dosage Forms
18.5.2.2.4. By Route of Administration
18.5.2.2.5. By Indication
18.5.2.2.6. By Distribution Channel
18.5.3. South Korea Market Analysis
18.5.3.1. Introduction
18.5.3.2. Market Analysis and Forecast by Market Taxonomy
18.5.3.2.1. By Product
18.5.3.2.2. By Type
18.5.3.2.3. By Dosage Forms
18.5.3.2.4. By Route of Administration
18.5.3.2.5. By Indication
18.5.3.2.6. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
19.3. Market Size (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Type
19.3.4. By Dosage Forms
19.3.5. By Route of Administration
19.3.6. By Indication
19.3.7. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Type
19.4.4. By Dosage Forms
19.4.5. By Route of Administration
19.4.6. By Indication
19.4.7. By Distribution Channel
19.5. Country Level Analysis & Forecast
19.5.1. Australia Market Analysis
19.5.1.1. Introduction
19.5.1.2. Market Analysis and Forecast by Market Taxonomy
19.5.1.2.1. By Product
19.5.1.2.2. By Type
19.5.1.2.3. By Dosage Forms
19.5.1.2.4. By Route of Administration
19.5.1.2.5. By Indication
19.5.1.2.6. By Distribution Channel
19.5.2. New Zealand Market Analysis
19.5.2.1. Introduction
19.5.2.2. Market Analysis and Forecast by Market Taxonomy
19.5.2.2.1. By Product
19.5.2.2.2. By Type
19.5.2.2.3. By Dosage Forms
19.5.2.2.4. By Route of Administration
19.5.2.2.5. By Indication
19.5.2.2.6. By Distribution Channel
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
20. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Billion) Analysis By Market Taxonomy, 2017 to 2022
20.3. Market Size (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. Northern Africa
20.3.1.4. South Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Product
20.3.3. By Type
20.3.4. By Dosage Forms
20.3.5. By Route of Administration
20.3.6. By Indication
20.3.7. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Type
20.4.4. By Dosage Forms
20.4.5. By Route of Administration
20.4.6. By Indication
20.4.7. By Distribution Channel
20.5. Country Level Analysis & Forecast
20.5.1. GCC Countries Market Analysis
20.5.1.1. Introduction
20.5.1.2. Market Analysis and Forecast by Market Taxonomy
20.5.1.2.1. By Product Type
20.5.1.2.2. By Route of Administration
20.5.1.2.3. By Indication
20.5.1.2.4. By Distribution Channel
20.5.2. Türkiye Market Analysis
20.5.2.1. Introduction
20.5.2.2. Market Analysis and Forecast by Market Taxonomy
20.5.2.2.1. By Product
20.5.2.2.2. By Type
20.5.2.2.3. By Dosage Forms
20.5.2.2.4. By Route of Administration
20.5.2.2.5. By Indication
20.5.2.2.6. By Distribution Channel
20.5.3. Northern Africa Market Analysis
20.5.3.1. Introduction
20.5.3.2. Market Analysis and Forecast by Market Taxonomy
20.5.3.2.1. By Product
20.5.3.2.2. By Type
20.5.3.2.3. By Dosage Forms
20.5.3.2.4. By Route of Administration
20.5.3.2.5. By Indication
20.5.3.2.6. By Distribution Channel
20.5.4. South Africa Market Analysis
20.5.4.1. Introduction
20.5.4.2. Market Analysis and Forecast by Market Taxonomy
20.5.4.2.1. By Product
20.5.4.2.2. By Type
20.5.4.2.3. By Dosage Forms
20.5.4.2.4. By Route of Administration
20.5.4.2.5. By Indication
20.5.4.2.6. By Distribution Channel
20.6. Market Trends
20.7. Key Market Participants - Intensity Mapping
20.8. Drivers and Restraints - Impact Analysis
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. GlaxoSmithKline PLC.
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Profitability by Market Segments (Product/Region)
22.3.1.4. Sales Footprint
22.3.1.5. Strategy Overview
22.3.2. Sanofi Consumer Healthcare
22.3.3. Himalaya Wellness Company
22.3.4. Sun Pharmaceutical Industries, Inc.
22.3.5. Bayer AG
22.3.6. Novartis AG
22.3.7. Cadila Pharmaceuticals
22.3.8. Bausch Health Companies Inc.
22.3.9. Alcon Vision LLC.
22.3.10. Merck & Co.
22.3.11. Dr. Reddy’s Laboratories, Ltd.
22.3.12. Viatris Inc.
22.3.13. Somerset Pharma, LLC
22.3.14. F. Hoffmann- La Roche Ltd.
22.3.15. Akorn Operating Company LLC
22.3.16. Teva Pharmaceutical Industries Ltd.
22.3.17. Speer laboratories
22.3.18. Glenmark Pharmaceuticals Limited
22.3.19. TerSera Therapeutics LLC
22.3.20. Pfizer Inc.
22.3.21. Johnson & Johnson Consumer Inc.
22.3.22. Pharmaceutical Specialties Inc.
22.3.23. Proctor & Gamble
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Antihistamine Market
